| ATC code J: Antiinfectives for systemic use |
|---|
|
| Human only |
| ATCvet only |
|
| Other ATC codes |
ATC code J Antiinfectives for systemic use is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QJ. ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.
National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version.
Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System | |
|---|---|
| gastrointestinal tract / metabolism (A) | |
| blood and blood forming organs (B) | |
| cardiovascular system (C) | |
| skin (D) | |
| genitourinary system (G) | |
| endocrine system (H) | |
| infections and infestations (J, P, QI) | |
| malignant disease (L01–L02) | |
| immune disease (L03–L04) | |
| muscles, bones, and joints (M) | |
| brain and nervous system (N) |
|
| respiratory system (R) | |
| sensory organs (S) | |
| other ATC (V) | |
| 30S |
| ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50S |
| ||||||||||||||||||||
| |||||||||||||||||||||
| Antifolates (inhibit bacterial purine metabolism, thereby inhibiting DNA and RNA synthesis) |
| ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Quinolones (inhibit bacterial topoisomerase and/or DNA gyrase, thereby inhibiting DNA replication) |
| ||||||||||||||||
| Anaerobic DNA inhibitors |
| ||||||||||||||||
| RNA synthesis |
| ||||||||||||||||
| |||||||||||||||||
| Glycopeptides Lipoglycopeptides | |
|---|---|
| Polymyxins | |
| Steroid antibacterials | |
| Imidazole derivatives | |
| Pleuromutilins | |
| Nitrofuran derivatives | |
| Other antibacterials | |
| Wall/ membrane |
| ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular |
| ||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||
| |||||||||||||||||||||||
| Nucleic acid inhibitor |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Protein synthesis inhibitor |
| ||||||||
| Cell envelope antibiotic |
| ||||||||
| Other/unknown | |||||||||
| Combinations | |||||||||
| |||||||||
| Baltimore I |
| ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hepatitis B (VII) | |||||||||||||||||||||
| Multiple/general |
| ||||||||||||||||||||
| |||||||||||||||||||||
| Hepatitis C |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis D | |||||||||
| Picornavirus | |||||||||
| Anti-influenza agents | |||||||||
| Multiple/general |
| ||||||||
| |||||||||
| Capsid inhibitors | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Entry/fusion inhibitors (Discovery and development) | |||||||||||||
| Integrase inhibitors (Integrase strand transfer inhibitors (INSTI)) | |||||||||||||
| Maturation inhibitors | |||||||||||||
| Protease Inhibitors (PI) (Discovery and development) |
| ||||||||||||
| Reverse-transcriptase inhibitors (RTIs) |
| ||||||||||||
| Combined formulations |
| ||||||||||||
| Pharmacokinetic boosters | |||||||||||||
| Experimental agents |
| ||||||||||||
| |||||||||||||
Immune sera and immunoglobulins (J06) | |||||
|---|---|---|---|---|---|
| Polyclonal antibodies |
| ||||
| Monoclonal antibodies | |||||
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||